University of North Carolina at Chapel Hill School of Medicine

Medications

Trial results of new drug for generalized myasthenia gravis

Argenx, a Belgium pharmaceutical company, recently announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living ...

Health

The skinny on fat: Debate rages on pros, cons of low-fat diet

(PhysOrg.com) -- In recent years a fierce debate has raged among nutrition experts over the wisdom of prevailing dietary guidelines that emphasize eating less saturated fat. Two experts from the UNC Department of Nutrition ...

page 7 from 31